Jobs
-
GlaxoSmithKline and Innoviva have presented data from the FULFIL study of its fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI versus Symbicort for COPD, reiterating that the data support the company’s plans to file an NDA for the product… Read more . . .
-
Adherium has announced that AstraZeneca will use Adherium’s SmartTouch Symbicort device in an upcoming 12-month clinical study of adherence in patients with COPD that is expected to enroll almost 400 US COPD patients. In July… Read more . . .
-
In its annual report for the fiscal year ended 30 April 2016, Consort Medical reports that its subsidiary Bespak experienced revenue growth of almost 11%, and CDMO Aesica, which Consort acquired in November 2014, experienced… Read more . . .
-
Hovione has announced that the official groundbreaking for the expansion of its facility in New Jersey took place on June 8, 2016. The expansion will double the capacity of the facility by adding 30,600 sq… Read more . . .
-
US generic inhalation solutions manufacturer Nephron Pharmaceuticals has licensed Apotex’s generic budesonide inhalation suspension, a generic version of AstraZeneca’s Pulmicort Respules, and subsequently launched the product in the US, the company said. Nephron will manufacture,… Read more . . .
-
Swedish DPI company Iconovo has announced a licensing and development deal with generics manufacturer Amneal Pharmaceuticals for a generic dry powder asthma/COPD therapy delivered by Iconovo’s ICOres multidose DPI. According to the company, the deal… Read more . . .
-
MannKind Corporation has announced that it signed an agreement with JDRF (formerly the Juvenile Diabetes Research Foundation) to collaborate on research focused on the use of Afrezza inhaled insulin in pediatric diabetes patients. JDRF is… Read more . . .
-
Device developer and manufacturer Phillips-Medisize has acquired Danish device company Medicom Innovation Partner (formerly Bang & Olufsen Medicom) for an undisclosed amount. The company said that, “The addition of Medicom’s capabilities expands Phillips-Medisize’s end-to-end injectable… Read more . . .
-
Acorda Therapeutics will present data from a Phase 1 study of its CVT-427 zolmitriptan DPI at the Annual Scientific Meeting of the American Headache Society, the company has announced. According to the company, the data… Read more . . .
-
Insmed has announced the withdrawal of its marketing authorization application for Arikayce inhaled liposomal amikacin for the treatment of nontuberculous mycobacteria (NTM) lung disease. The MAA was submitted to the European Medicines Agency in 2014,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland